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Abstract
Background: The associations between pulmonary diseases (asthma, chronic obstructive pulmonary disease [COPD],
and tuberculosis [TB]) and subsequent lung cancer risk have been reported, but few studies have investigated the
association with different histologic types of lung cancer.
Methods: Patients newly diagnosed with lung cancer from 2004 to 2008 were identified from the National Health
Insurance Research Database in Taiwan. Histologic types of lung cancer were further confirmed using the Taiwan
Cancer Registry Database. Cox proportional hazards regression was used to calculate the hazard ratio (HR) of asthma,
COPD, and TB and to estimate the risk of specific types of lung cancer.
Results: During the study period, 32,759 cases of lung cancer were identified from 15,219,024 insurants aged 20 years
and older. In men and women, the adjusted HR estimates of squamous cell carcinoma were respectively 1.37 (95 %
confidence interval [CI], 1.21–1.54) and 2.10 (95 % CI, 1.36–3.23) for TB, 1.52 (95 % CI, 1.42–1.64) and 1.50
(95 % CI, 1.21–1.85) for asthma, and 1.66 (95 % CI, 1.56–1.76) and 1.44 (95 % CI, 1.19–1.74) for COPD.
Similarly, the adjusted HR estimates of adenocarcinoma were respectively 1.33 (95 % CI, 1.19–1.50) and 1.86
(95 % CI, 1.57–2.19) for TB, 1.13 (95 % CI, 1.05–1.21) and 1.18 (95 % CI, 1.09–1.28) for asthma, and 1.50 (95 % CI, 1.42–
1.59) and 1.33 (95 % CI, 1.25–1.42) for COPD. The HRs of small cell carcinoma were respectively 1.24 (95 % CI, 1.01–1.52)
and 2.23 (95 % CI, 1.17–4.25) for TB, 1.51 (95 % CI, 1.35–1.69) and 1.63 (95 % CI, 1.16–2.27) for asthma, and 1.39 (95 % CI,
1.26–1.53) and 1.78 (95 % CI, 1.33–2.39) for COPD.
Conclusions: Asthma, COPD, and TB were associated with an increased risk of all major subtypes of lung cancer. The
risk was the highest among women with TB.
Keywords: Asthma, Chronic obstructive pulmonary disease, Lung adenocarcinoma, Small cell carcinoma, Squamous
cell carcinoma, Tuberculosis
Background
Lung cancer is the second leading diseases contributing to
years of life lost because of premature mortality [1].
Among histologic types of lung cancer, adenocarcinoma is
the most common subtype in Asians but not in Europeans
[2, 3]. Typical risk factors for lung cancer include smoking
and exposure to arsenic, chromium, radon, or air pollu-
tion [4, 5]. Smoking is the major risk factor for lung can-
cer, particularly squamous cell carcinoma (SqCC) [6].
However, a previous study demonstrated that most
Taiwanese women with lung cancer are non-smokers [7].
A vast majority of smokers do not seem to develop lung
cancer. Although smoking is a potential risk factor, other
factors may also be linked to the increased risk of lung
cancer.
Recent studies have concluded that chronic inflamma-
tion may be linked to lung carcinogenesis [8]. Among in-
trinsic pulmonary diseases, chronic obstructive pulmonary
* Correspondence: Liawyp@csmu.edu.tw
1Department of Public Health and Institute of Public Health, Chung Shan
Medical University, No. 110, Sec. 1 Jianguo N. Rd., Taichung City 40201,
Taiwan
2Department of Family and Community Medicine, Chung Shan Medical
University Hospital, 40201 Taichung City, Taiwan
Full list of author information is available at the end of the article
© 2015 Huang et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Huang et al. BMC Cancer  (2015) 15:834 
DOI 10.1186/s12885-015-1847-z
disease (COPD) [9, 10], asthma [11], and tuberculosis
(TB) [12] are associated with lung cancer. Smokers
with COPD have a higher risk of SqCC [13, 14].
Asthma is associated with an increased risk of SqCC and
small cell carcinoma (SmCC) but is weakly associated with
adenocarcinoma [15, 16]. TB is also associated with an in-
creased risk of SqCC and adenocarcinoma but not SmCC
[17]. An association between TB and lung adenocarcin-
oma has been reported in non-westernized countries [18].
Furthermore, the association of lung cancer with diabetes
[19] and dyslipidemia [20–22] has been reported. Data on
pulmonary diseases and specific histologic types of lung
cancer are considerable limited in Taiwan.
For a detailed evaluation of the relationship between
pulmonary diseases and histologic types of lung cancer,
a population-based cohort study is highly desirable.
However, few such studies have been conducted. This
study assessed whether pulmonary diseases are associ-




The National Health Insurance Research Database
(NHIRD) contains enrollment files, claims data, cata-
strophic illness files, and treatment registries. The national
health insurance program covers more than 99 % of the
population of Taiwan. The NHIRD is one of the largest
administrative health care databases that is broadly used
in academic studies [23–25]. This study used the linked
databases of the NHIRD, Taiwan Cancer Registry Data-
base (TCRD), and National Death Registry Database
(NDRD) with the permission of the Department of Statis-
tics, Ministry of Health and Welfare of Taiwan. The
source data was encrypted and the data extracted was an-
onymous. This study was approved by the Institutional
Review Board of the Chung-Shan Medical University
Hospital, Taiwan.
Identification of Patients With Lung Cancer
In this study, 17,859,318 residents aged 20 years and older
were initially enrolled. We excluded patients diagnosed
with lung cancer before 2003 (n = 39,623) and those with
incomplete information on sex (n = 2,600,565), registry
data (n = 5), and death (n = 101). Finally, 15,219,024
patients (8,002,536 men and 7,216,488 women) were
enrolled in this study. Patients newly diagnosed with lung
cancer in 2004 were followed up until death, loss to
follow-up, or the study end in 2008. Lung cancer was
identified using the International Classification of Dis-
eases, Ninth Revision, Clinical Modification (ICD-9-CM)
code 162.
Furthermore, histologic types of lung cancer were con-
firmed using the TCRD. The registry contains data on
cancer types, initial tumor stages, and histology. Lung
cancer was identified using the ICD-9-CM code 162 or
ICD 10 codes C34.0, C34.1, C34.2, C34.3, C34.8, and
C34.9 in the TCRD. Morphological diagnoses were
determined using the ninth revision of the International
Classification of Diseases for Oncology (ICD-O) on the
basis of the following ICD-O codes: 80522, 80523,
80702, 80703, 80713, 80723, 80733, 80743, 80763,
80823, 80833, and 80843 for lung SqCC; 80503, 81402,
81403, 81413, 81433, 82113, 82503, 82513, 82523,
82553, 82603, 83103, 83233, 84603, 84803, 84813,
84903, and 85003 for adenocarcinoma; 80023, 80412,
80413, 80423, 80433, 80453, and 94733 for SmCC; and
80123, 80143, 80203, 80213, 80303, and 80313 for large
cell carcinoma.
The linked databases were used to retrieve information
on the age of lung cancer diagnosis, follow-up time (in
person-years), and survival time and to minimize poten-
tially unconfirmed cancer diagnoses.
Variables of Exposure
Baseline variables included age, sex, urbanization level,
geographical area, low income, and comorbidities. To re-
duce bias, the diagnoses of pulmonary diseases and co-
morbidities were confirmed by more than two
outpatient visits or one admission between 2001 and
2003. Pulmonary diseases and comorbidities were de-
fined using the following ICD-9-CM codes: asthma
(493), COPD (490, 491, 492, 494, and 496), TB (010 –
012, and137.0), chronic kidney disease (585 and 586),
type II diabetes mellitus (250, which excludes type I dia-
betes mellitus), and hyperlipidemia (272). Smoking, a
major risk factor for lung cancer, COPD, and other cancer
types are not available in the NHIRD [26, 27]; hence, this
prevented direct adjustment for all possible confounders.
However, smoking -related cancers such as lip, oral cavity,
nasal cavity, pharynx, larynx, esophagus (ICD-9-CM
codes: 140–150 and 160–161), pancreas (ICD-9-CM code
157), kidney, and bladder cancers (ICD-9-CM codes 188
and 189) were adjusted [28].
Statistical Analyses
All statistical analyses were conducted using the SAS
statistical package (Version 9.3; SAS Institute, Inc., Cary,
NC). The characteristics of the study population were
compared using the chi-square test. A p value of < 0.05
was statistically significant. To evaluate the effect of age,
patients were classified according to sex and age (20–39,
40–49, 50–59, 60–69, 70–79, and ≥80 years). All cities
and towns were divided into three urbanization levels:
low, medium, and high. The Cox proportional hazards re-
gression model was used to estimate the hazard ratios
(HRs) of histologic types of lung cancer while controlling
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Table 1 Characteristics of the Study Population
Lung cancer (N = 32759) Non-lung cancer(N = 15186265) p-value
Lung diseases (%)
Tuberculosis 1052 (3.2) 110469 (0.7) < 0.001
Asthma 4380 (13.4) 747889 (4.9) < 0.001
COPD 7883 (24.1) 1201101 (7.9) < 0.001
Sex (%) < 0.001
Men 22872 (69.8) 7979664 (52.6)
Women 9887 (30.2) 7206601 (47.4)
Age (years, %) < 0.001
20–39 1049 (3.2) 7221512 (47.6)
40–49 3580 (10.9) 3464916 (22.8)
50–59 5937 (18.1) 2209547 (14.6)
60–69 7374 (22.5) 1036090 (6.8)
70–79 10544 (32.2) 823322 (5.4)
≧80 4275 (13.1) 430878 (2.8)
Low income (%)a 889 (2.7) 245045 (1.6) < 0.001
Comorbidities (%)
Diabetes 5680 (17.3) 1060714 (7.0) < 0.001
Hyperlipidemia 5988 (18.3) 1347931 (8.9) < 0.001
Chronic kidney disease 961 (2.9) 149730 (1.0) < 0.001
Smoking-related cancersb 777 (2.4) 103201 (0.7) < 0.001
Geographical area (%) < 0.001
Taipei City 9236 (28.2) 4851844 (32.0)
North 3920 (12.0) 1961790 (12.9)
Central 6393 (19.5) 2936377 (19.3)
South 6614 (20.2) 2366398 (15.6)
Kaohsiung-Pingtung 5489 (16.8) 2628117 (17.3)
East 1107 (3.3) 441739 (2.9)
Urbanization (%) < 0.001
High 13889 (42.4) 7519048 (49.5)
Mid 12338 (37.7) 5575331 (36.7)
Low 6532 (19.9) 2091866 (13.8)
Death in 2004–2008 (%) 27718 (84.6) 648922 (4.3) < 0.001
Follow-up time 84505 73801819
(person-year)
Histologic type (%)
Squamous cell carcinoma 6637 (20.3)
Adenocarcinoma 15490 (47.3)
Small cell carcinoma 3019 (9.2)
Large cell carcinoma 240 (0.7)
Others 7373 (22.5)
aIncome is lower than the level required for charging premium
bSmoking-related cancers included lip, oral cavity, nasal cavity, pharynx, larynx, and esophagus, pancreas, kidney and bladder cancers that were prior to a
diagnosis of lung cancer
Abbreviations: COPD, chronic obstructive pulmonary disease
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for age, geographical area, urbanization level, low income,
and comorbidities.
Results
During the study period, 32,759 cases of lung cancer
were identified. Of all patients diagnosed, 47.3 % had
adenocarcinoma (M: F, 8,778: 6,712), 20.3 % had SqCC
(5,877: 760), 9.2 % had SmCC (2,751: 268), 0.7 % had
large cell carcinoma (183: 57), and 23.2 % had other dis-
eases (5,283: 2,090). The demographic characteristics
and comorbidities of the study population are displayed
in Table 1. Patients with lung cancer had higher rates of
asthma, COPD, TB, hyperlipidemia, diabetes, chronic
kidney disease, and smoking-related cancer than individ-
uals without lung cancer did.
In Table 2, Cox regression analysis revealed a signifi-
cantly high incidence of lung cancer in male patients
with COPD (HR, 1.56; 95 % confidence interval [CI],
1.51–1.61), asthma (HR, 1.36; 95 % CI, 1.30–1.41), TB
(HR, 1.35; 95 % CI, 1.26–1.44), low income (HR, 1.14;
95 % CI, 1.05–1.23), hyperlipidemia (HR, 1.07; 95%CI,
1.04–1.11), and smoking-related cancer (HR, 1.79; 95 %
CI, 1.68–1.90). The risk of lung cancer was high in
female patients with TB (HR, 1.97; 95 % CI, 1.73–2.24),
COPD (HR, 1.33; 95 % CI, 1.26–1.41), asthma (HR, 1.26;
95 % CI, 1.18–1.34), low income (HR, 1.36; 95 % CI,
1.20–1.54), hyperlipidemia (HR, 1.13; 95 % CI, 1.07–
1.19), and smoking related cancer (HR, 2.28; 95 % CI,
2.02–2.57).
Table 3 presents the adjusted HRs for SqCC stratified by
sex. The incidence of SqCC was high in male patients with
COPD (HR, 1.66; 95 % CI, 1.56–1.76), asthma (HR, 1.52;
95 % CI, 1.42–1.64), TB (HR, 1.37; 95 % CI, 1.21–1.54),
and smoking-related cancer (HR, 2.58; 95 % CI, 2.33–
2.86). The HRs of SqCC in women with TB, asthma,
COPD, and smoking-related cancer were 2.10 (95 % CI,
1.36–3.23), 1.50 (95 % CI, 1.21–1.85), 1.44 (95 % CI, 1.19–
1.74), and 3.98 (95 % CI, 2.84–5.57), respectively.
Table 4 provides the HRs of adenocarcinoma strati-
fied by sex. The risk of adenocarcinoma was high in
male patients with COPD (HR, 1.50; 95 % CI, 1.42–
1.59), TB (HR, 1.33; 95 % CI, 1.19–1.50), asthma (HR,
1.13; 95 % CI, 1.05–1.21), hyperlipidemia (HR, 1.19;
95 % CI, 1.12–1.26), and smoking-related cancer (HR,
1.46; 95 % CI, 1.30–1.63). The HRs of adenocarcin-
oma in female patients with TB, COPD, asthma,
hyperlipidemia, and smoking-related cancer were 1.86
(95 % CI, 1.57–2.19), 1.33 (95 % CI, 1.25–1.42), 1.18
(95 % CI, 1.09–1.28), 1.19 (95 % CI, 1.12–1.26), and
2.00 (95 % CI, 1.71–2.35), respectively.
Table 5 displays the adjusted HRs of SmCC stratified
by sex. The risk of SmCC was high in male patients with
Table 2 Hazard Ratios and 95 % Confidence Intervals of Lung Cancer Stratified by Sex
Male Female
HR (95 % CI) P value HR (95 % CI) P value
Lung diseases
Tuberculosis 1.35 (1.26–1.44) < 0.001 1.97 (1.73–2.24) <0.001
Asthma 1.36 (1.30–1.41) < 0.001 1.26 (1.18–1.34) <0.001
COPD 1.56 (1.51–1.61) < 0.001 1.33 (1.26–1.41) <0.001
Low incomea 1.14 (1.05–1.23) 0.001 1.36 (1.20–1.54) < 0.001
Age group
20–39 0.14 (0.13–0.16) < 0.001 0.15 (0.14–0.17) < 0.001
40–49 Reference Reference
50–59 2.80 (2.65–2.96) < 0.001 2.17 (2.03–2.31) < 0.001
60–69 7.30 (6.93–7.69) < 0.001 4.35 (4.07–4.65) < 0.001
70–79 12.70 (12.08–13.34) < 0.001 6.70 (6.26–7.16) < 0.001
≧80 8.91 (8.43–9.43) < 0.001 5.72 (5.30–6.17) < 0.001
Comorbidities
Diabetes 1.00 (0.96–1.04) 0.926 1.01 (0.96–1.07) 0.689
Hyperlipidemia 1.07 (1.04–1.11) <0.001 1.13 (1.07–1.19) <0.001
Chronic kidney disease 0.90 (0.84–0.97) 0.004 0.87 (0.76–0.99) 0.035
Smoking–related cancersb 1.79 (1.68–1.90) <0.001 2.28 (2.02–2.57) <0.001
Adjustments were made to estimate HRs for all covariates (lung diseases, low income, age, comorbidities, urbanization and geographic area)
aIncome is lower than the level required for charging premium
bSmoking-related cancers included lip, oral cavity, nasal cavity, pharynx, larynx, and esophagus, pancreas, kidney and bladder cancers that were prior to a
diagnosis of lung cancer
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio
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asthma (HR, 1.51; 95 % CI, 1.35–1.69), COPD (HR, 1.39;
95 % CI, 1.26–1.53), TB (HR, 1.24; 95 % CI, 1.01–1.52),
and smoking-related cancer (HR, 1.35; 95 % CI, 1.10–
1.66). The HRs of SmCC in women with TB, COPD,
asthma, and smoking-related cancer were 2.23 (95 % CI,
1.17–4.25), 1.78 (95 % CI, 1.33–2.39), 1.63 (95 % CI,
1.16–2.27), and 3.71 (95 % CI, 2.12–6.49), respectively.
Discussion
This study demonstrated that male and female patients
with TB, asthma, and COPD had increased risks of lung
SqCC, adenocarcinoma, and SmCC. Determining risk
factors for specific types of lung cancer can help physi-
cians gain a detailed understanding of the etiology of
lung cancer and therefore identify the high-risk popula-
tion for screening. To the best of our knowledge, no
study has investigated the association between pulmon-
ary diseases and histologic types of lung cancer. Accord-
ing to the study results, heterogeneity was observed in
the risk factors for lung cancer and the different histo-
logic types in male and female patients.
A population-based, case-control study of female non-
smokers revealed an increased risk of lung cancer in pa-
tients with TB who were diagnosed before the age of
21 years [29]. The incidence rate ratio of lung cancer in
the TB cohorts was 1.98 (95%CI, 1.37–2.83) 2 – 4 years
after TB infection [12]. A hospital-based, case-control
study involving interviews of 226 female nonsmokers
with lung cancer and 279 controls demonstrated that TB
increased the risk of lung cancer (odds ratio [OR], 4.7;
95 % CI, 1.6–13.2) [30]. Yu et al. found an increased risk
of lung cancer among patients with TB (HR, 3.32; 95 %
CI, 2.70–4.09), which was higher than that of COPD
(HR, 2.30; 95 % CI, 2.07–2.55) [28]. A systematic review
identified a direct relationship between preexisting TB
and lung cancer, particularly adenocarcinoma (relative
risk [RR], 1.6; 95 % CI, 1.2–2.1) [18]. A study conducted
in Taiwan demonstrated that TB was an independent
risk factor for SqCC, SmCC, and adenocarcinoma in
men and women [6]. Such an association is particularly
crucial in Taiwan, where the prevalence of TB is high
[31, 32]. Compared with asthma and COPD, TB appears
to have a stronger association with lung cancer among
women. Additional studies are necessary to assess the
possible mechanisms of this association.
In this study, COPD was associated with the risk of
the major types of lung cancer. Chronic airway inflam-
mation is a major risk factor for COPD and is also asso-
ciated with an increased risk of lung cancer [13]. A
study involving the 22-year follow-up of 5,402
Table 3 Hazard Ratios and 95 % Confidence Intervals of Squamous Cell Carcinoma Stratified by Sex
Male Female
HR (95 % CI) P value HR (95 % CI) P value
Lung diseases
Tuberculosis 1.37 (1.21–1.54) < 0.001 2.10 (1.36–3.23) <0.001
Asthma 1.52 (1.42–1.64) < 0.001 1.50 (1.21–1.85) <0.001
COPD 1.66 (1.56–1.76) < 0.001 1.44 (1.19–1.74) <0.001
Low incomea 1.15 (0.99–1.34) 0.066 2.35 (1.66–3.32) <0.001
Age group
20–39 0.12 (0.09–0.15) < 0.001 0.14 (0.09–0.20) <0.001
40–49 Reference Reference
50–59 3.59 (3.16–4.08) < 0.001 2.05 (1.62–2.59) <0.001
60–69 12.38 (10.98–13.95) < 0.001 4.47 (3.54–5.65) <0.001
70–79 21.39 (19.03–24.04) < 0.001 6.23 (4.89–7.92) <0.001
≧80 13.36 (11.74–15.19) < 0.001 4.66 (3.51–6.19) <0.001
Comorbidities
Diabetes 1.00 (0.93–1.07) 0.922 1.14 (0.94–1.39) 0.169
Hyperlipidemia 0.98 (0.92–1.06) 0.668 0.97 (0.80–1.17) 0.717
Chronic kidney disease 0.85 (0.73–0.97) 0.020 0.85 (0.53–1.34) 0.473
Smoking–related cancersb 2.58 (2.33–2.86) < 0.001 3.98 (2.84–5.57) <0.001
Adjustments were made to estimate HRs for all covariates (lung diseases, low income, age, comorbidities, urbanization and geographic area)
aIncome is lower than the level required for charging premium
bSmoking-related cancers included lip, oral cavity, nasal cavity, pharynx, larynx, and esophagus, pancreas, kidney and bladder cancers that were prior to a
diagnosis of lung cancer
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio
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participants concluded that moderate-to-severe obstruct-
ive pulmonary disease was associated with a higher risk of
incident lung cancer (HR, 2.8; 95 % CI, 1.8–4.4) [33]. Den-
holm et al. found that chronic bronchitis and emphysema
were positively associated with lung cancer after adjusting
for other respiratory diseases and smoking (OR, 1.33;
95 % CI, 1.20–1.48 for men; OR, 1.50; 95 % CI, 1.21–1.87
for women) [34]. The prevalence of smoking is almost 10-
fold higher in Taiwanese men than that in women [35].
However, the smoking status of the study population was
not available. This may be the reason for the observed dif-
ferences between men and women. Chronic bronchitis
and emphysema increased the risk of SqCC (HR, 1.54;
95 % CI, 1.09–2.18) independent of smoking [36]. COPD
also increased the risk of SqCC in smokers [13]. Pesch et
al. performed a pooled analysis of case-control studies in-
cluding 13,169 cases and 16,010 controls from Europe and
Canada [37]. Their analysis demonstrated that adenocar-
cinoma was the most prevalent subtype in never-smokers
and women. The ORs were elevated for exposure to
cigarette smoke and were higher for SqCC and SmCC
than for adenocarcinoma. Freedman et al. recruited
279,214 men and 184,623 women aged 50–71 years from
eight states in the United States to evaluate whether
women were more susceptible to lung cancer caused by
cigarette smoking than men [38]. Their results illustrated
that the HRs of adenocarcinoma, SmCC, and undifferenti-
ated tumors were similar between men and women
among ex-smokers and current smokers. However, among
current smokers, the HR of SqCC in men was approxi-
mately 2-fold higher than that in women.
This study also suggests that patients with asthma are at
an increased risk of three histological types (SqCC, adeno-
carcinoma, and SmCC) of lung cancer. Asthma is one of
the most common chronic airway diseases and affects 300
million people of all ages and ethnicities [39]. In Taiwan,
the prevalence of asthma has increased to 11.9 % [40].
Because asthma causes complex chronic airway inflamma-
tion, it has been hypothesized to lead to carcinogenesis
[8]. Case-control studies have produced varied results for
the association between asthma and lung cancer [41, 42].
In a Swedish cohort with a hospital-discharge diagnosis of
asthma, the standardized incidence rate ratio of lung cancer
was 1.51 in men (95 % CI, 1.38–1.65) and 1.78 in women
(95 % CI, 1.55–2.03), and the risk of histologic types of lung
cancer was higher in patients with SqCC and SmCC [16].
In a meta-analysis, the RRs were 1.69 (95 % CI, 1.26–2.26)
for SqCC, 1.71 (95 % CI, 0.99–2.95) for SmCC, and 1.09
(95 % CI, 0.88–1.36) for adenocarcinoma [15].
In this study, hyperlipidemia was also associated with
an increased risk of adenocarcinoma. Hyperlipidemia is
a component of metabolic syndrome and is associated
Table 4 Hazard Ratios and 95 % Confidence Intervals of Adenocarcinoma Stratified by Sex
Male
HR (95 % CI) P value HR (95 % CI) P value
Lung diseases
Tuberculosis 1.33 (1.19–1.50) < 0.001 1.86 (1.57–2.19) < 0.001
Asthma 1.13 (1.05–1.21) < 0.001 1.18 (1.09–1.28) < 0.001
COPD 1.50 (1.42–1.59) < 0.001 1.33 (1.25–1.42) < 0.001
Low incomea 1.07 (0.94–1.22) 0.322 1.18 (1.00–1.39) 0.055
Age group
20–39 0.15 (0.13–0.17) < 0.001 0.15 (0.13–0.17) < 0.001
40–49 Reference Reference
50–59 2.45 (2.27–2.64) < 0.001 2.17 (2.01–2.34) < 0.001
60–69 5.23 (4.85–5.63) < 0.001 4.10 (3.80–4.44) < 0.001
70–79 8.15 (7.59–8.76) < 0.001 5.93 (5.46–6.43) < 0.001
≧80 5.61 (5.15–6.11) < 0.001 4.03 (3.64–4.45) < 0.001
Comorbidities
Diabetes 0.95 (0.90–1.01) 0.106 0.95 (0.89–1.02) 0.128
Hyperlipidemia 1.19 (1.12–1.26) < 0.001 1.19 (1.12–1.26) < 0.001
Chronic kidney disease 0.86 (0.76–0.98) 0.019 0.84 (0.71–0.99) 0.040
Smoking–related cancersb 1.46 (1.30–1.63) <0.001 2.00 (1.71–2.35) < 0.001
Adjustments were made to estimate HRs for all covariates (lung diseases, low income, age, comorbidities, urbanization and geographic area)
aIncome is lower than the level required for charging premium
bSmoking-related cancers included lip, oral cavity, nasal cavity, pharynx, larynx, and esophagus, pancreas, kidney and bladder cancers that were prior to a
diagnosis of lung cancer
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio
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with insulin resistance [43]. Hyperinsulinemia, hypergly-
cemia, and chronic inflammation play a vital role in the
neoplastic process [44]. High serum triglyceride concen-
trations are associated with an increased risk of lung
cancer (fourth vs first quartile: HR, 1.94; 95 % CI, 1.47–
2.54) [22]. Additional studies are required to assess the
association between hyperlipidemia and adenocarcinoma.
Evaluating the temporal relationship between pulmon-
ary diseases and subsequent lung cancer in case-control
studies is difficult. Previous studies might have yielded
inconclusive results because they focused mainly on the
high-risk populations of heavy smokers. This study has
several strengths. First, our data were retrieved from com-
bined databases (NHIRD, TCRD and NDRD) that in-
cluded all residents; hence, recall and selection bias was
minimized. Second, the histologic type of lung cancer was
confirmed using the TCRD. Nevertheless, our study has
some limitations. First, the NHIRD does not contain
detailed clinical data and information on lifestyle-related
factors such as smoking, obesity, physical inactivity, diet-
ary habits, and family history, which are closely associated
with lung cancer. Smoking is a major confounding factor
of lung cancer. Biases were minimized by adjusting for
COPD and smoking-related cancer. Second, patients with
asthma, COPD, and TB may have used medications that
may have complicated their conditions. This study did not
evaluate the effects of drugs.
Conclusions
This study demonstrated that asthma, COPD, and TB
were associated with increased risks of all major sub-
types of lung cancer. The risk was the highest among
women with TB.
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Table 5 Hazard Ratios and 95 % Confidence Intervals of Small Cell Carcinoma by Stratified by Sex
Male Female
HR (95 % CI) P value HR (95 % CI) P value
Lung diseases
Tuberculosis 1.24 (1.01–1.52) 0.037 2.23 (1.17–4.25) 0.015
Asthma 1.51 (1.35–1.69) < 0.001 1.63 (1.16–2.27) 0.005
COPD 1.39 (1.26–1.53) < 0.001 1.78 (1.33–2.39) <0.001
Low incomea 0.96 (0.75–1.23) 0.738 2.91 (1.80–4.68) < 0.001
Age group
20–39 0.09 (0.06–0.12) < 0.001 0.10 (0.04–0.27) < 0.001
40–49 Reference Reference
50–59 3.47 (2.93–4.10) < 0.001 3.73 (2.31–6.01) < 0.001
60–69 10.60 (9.04–12.43) < 0.001 10.86 (6.80–17.33) < 0.001
70–79 17.1 (14.64–19.98) < 0.001 14.19 (8.73–23.07) < 0.001
≧80 9.61 (8.03–11.49) < 0.001 14.97 (8.97–24.97) < 0.001
Comorbidities
Diabetes 1.07 (0.96–1.18) 0.226 1.24 (0.92–1.69) 0.162
Hyperlipidemia 1.09 (0.98–1.21) 0.100 0.84 (0.61–1.15) 0.264
Chronic kidney disease 0.70 (0.55–0.89) 0.003 0.90 (0.44–1.84) 0.774
Smoking-related cancersb 1.35 (1.10–1.66) 0.004 3.71 (2.12–6.49) < 0.001
Adjustments were made to estimate HRs for all covariates (lung diseases, low income, age, comorbidities, urbanization and geographic area)
aIncome is lower than the level required for charging premium
bSmoking-related cancers included lip, oral cavity, nasal cavity, pharynx, larynx, and esophagus, pancreas, kidney and bladder cancers that were prior to a
diagnosis of lung cancer
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio
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